Anticoagulant hirudin variants and methods for their production
    1.
    发明授权
    Anticoagulant hirudin variants and methods for their production 失效
    抗凝血水蛭素变体及其生产方法

    公开(公告)号:US5767235A

    公开(公告)日:1998-06-16

    申请号:US367758

    申请日:1995-01-03

    CPC分类号: C07K14/815 A61K38/00

    摘要: The present invention relates to hirudin variants having high anti-thrombin and anti-platelet activity, methods for producing them, and anti-coagulants having said variants as active ingredients. Hirudin variants shown in formula (I) having tyrosine residues or having their hydroxyl group sulfated. Methods for producing hirudin variants by sulfating hydroxyl group of said tyrosine residues, and anti-coagulants having hirudin variants shown in formula (I) as active ingredients. Phe-Glu-A-Ile-Pro-B-Tyr(R)-Tyr(R) (I) �In the formula, A represents Glu or Pro, B represents Glu, Tyr (R), Glu-Asp or Glu-Tyr(R), and (R) represents the hydroxy group or its sulfated ester (--O--SO.sub.3 H) of tyrosine residue.!

    摘要翻译: 本发明涉及具有高抗凝血酶和抗血小板活性的水蛭素变体,其制备方法和具有所述变体作为活性成分的抗凝血剂。 具有酪氨酸残基或其羟基硫酸化的式(I)所示的水蛭素变体。 通过将所述酪氨酸残基的羟基硫酸化制备水蛭变体的方法和具有式(I)所示水蛭素变体的抗凝血剂作为活性成分。Phe-Glu-A-Ile-Pro-B-Tyr(R)-Tyr R)(I)[式中,A表示Glu或Pro,B表示Glu,Tyr(R),Glu-Asp或Glu-Tyr(R),(R)表示羟基或其硫酸酯( - O-SO3H)酪氨酸残基。

    Method for the diagnosis of rheumatoid arthritis
    2.
    发明授权
    Method for the diagnosis of rheumatoid arthritis 失效
    用于诊断湿疹病毒的方法

    公开(公告)号:US5190861A

    公开(公告)日:1993-03-02

    申请号:US348701

    申请日:1989-04-25

    IPC分类号: C07K16/38

    CPC分类号: C07K16/38

    摘要: A method for diagnosing rheumatoid arthritis, which is characterized by enzyme-immunologically measuring the amount of collagenase inhibitor present in sera, plasmas or synovial fluids by way of a sandwich assay wherein two different monoclonal antibodies which specifically bind to different antigenic determinants of the collagenase inhibitor are used, and comparing the measured amount with that for normal subjects.

    摘要翻译: PCT No.PCT / JP88 / 00846 Sec。 371日期:1989年4月25日 102(e)日期1989年4月25日PCT提交1988年8月25日PCT公布。 出版物WO89 / 02078 日本1993年3月9日。一种用于诊断类风湿性关节炎的方法,其特征在于通过夹心测定法酶联免疫测量存在于血清,血浆或滑液中的胶原酶抑制剂的量,其中两种不同的单克隆抗体特异性结合 使用胶原酶抑制剂的不同抗原决定簇,并将测定的量与正常受试者的量进行比较。

    Method for the diagnosis of hepatic carcinoma
    3.
    发明授权
    Method for the diagnosis of hepatic carcinoma 失效
    用于诊断胃癌的方法

    公开(公告)号:US5175084A

    公开(公告)日:1992-12-29

    申请号:US382789

    申请日:1989-06-23

    IPC分类号: C07K16/30 C07K16/38

    CPC分类号: C07K16/303 C07K16/38

    摘要: A method for diagnosing hepatic carcinoma, which is characterized by enzyme-immunologically measuring the amount of collagenase inhibitor present in sera, plasmas of synovial fluids by way of a sandwich assay wherein two different monoclonal antibodies which specifically bind to different antigenic determinants of the collagenase inhibitor are used, and comparing the measured amount with that for normal subjects.

    摘要翻译: PCT No.PCT / JP88 / 01103 Sec。 371日期1989年6月23日第 102(e)日期1989年6月23日PCT提交1988年10月28日PCT公布。 公开号WO89 / 03997 日期:1989年5月5日。一种用于诊断肝癌的方法,其特征在于通过夹心测定酶联免疫学测量存在于血清,血浆等离子体中的胶原酶抑制剂的量,其中两种不同的单克隆抗体特异性结合不同的 使用胶原酶抑制剂的抗原决定簇,并将测定的量与正常受试者的量进行比较。

    Method for determining beta-subunit of human prolyl 4-hydroxylase by
immunoassay to detect hepatic disease
    4.
    发明授权
    Method for determining beta-subunit of human prolyl 4-hydroxylase by immunoassay to detect hepatic disease 失效
    通过免疫测定法检测肝脏疾病的人脯氨酰4-羟化酶的β-亚单位的方法

    公开(公告)号:US5137807A

    公开(公告)日:1992-08-11

    申请号:US380751

    申请日:1989-07-17

    摘要: The present invention is directed to a method for detecting hepatic diseases which are associated with fibrosis by determining the level of human prolyl hydroxylase in a serum sample which comprises:(a) contacting a serum sample of a patient suspected of having said hepatic disease associated with fibrosis with a monoclonal antibody specific to the .beta.-subunit of human prolyl hydroxylase to form an antigen antibody complex bound on a solid support;(b) contacting said antigen antibody complex bound on said solid support with an enzyme-labeled monoclonal or enzyme-labeled polyclonal antibody specific to human prolyl hydroxylase to form an antibody antigen enzyme-labeled antibody complex; and(c) measuring the amount of enzyme activity of said bound antibody antigen enzyme-labeled antibody complex to determine the level of human prolyl hydroxylase present in said serum sample.

    摘要翻译: 本发明涉及通过测定血清样品中人脯氨酰羟化酶水平来检测与纤维化相关的肝病的方法,该方法包括:(a)使疑似患有所述肝病的患者的血清样品与 纤维化与对人脯氨酰羟化酶的β亚单位特异的单克隆抗体形成结合在固体支持物上的抗原抗体复合物; (b)将结合在所述固体支持物上的所述抗原抗体复合物与人脯氨酰羟化酶特异性的酶标记的单克隆或酶标记的多克隆抗体接触以形成抗体抗原酶标记的抗体复合物; 和(c)测量所述结合的抗体抗体酶标记的抗体复合物的酶活性的量以确定存在于所述血清样品中的人脯氨酰羟化酶的水平。

    Highly water-soluble metalloproteinase inhibitors
    6.
    发明授权
    Highly water-soluble metalloproteinase inhibitors 失效
    高度水溶性金属蛋白酶抑制剂

    公开(公告)号:US6147114A

    公开(公告)日:2000-11-14

    申请号:US945356

    申请日:1997-10-24

    摘要: New compounds of the general formula (I) ##STR1## (wherein R.sup.1 is a hydrogen atom, or a hydroxyl, aryl (C.sub.1 -C.sub.6)alkylene or --A--SOn--B group (A is a (C.sub.1 -C.sub.6) alkylene group; B is a (C.sub.1 -C.sub.6) alkyl, (C.sub.1 -C.sub.6) acyl, aryl or heterocyclyl group; n is 0, 1 or 2), R.sup.2 is a hydrogen atom, or a (C.sub.1 -C.sub.6) alkyl, (C.sub.1 -C.sub.6) alkyloxy 10 or (C.sub.1 -C.sub.6) alkylthio group, R.sup.3 and R.sup.4 are identical or different, representing a hydrogen atom, or a (C.sub.1 -C.sub.6) alkyl, aryl or aryl(C.sub.1 -C.sub.6)alkylene group, R.sup.5 is a --Y--C or C group (Y is a (C.sub.1 -C.sub.6) alkylene group, an oxygen atom, an imino group or a (C.sub.1 -C.sub.6) alkyleneimino group, C is a sulfonic acid, phosphonic acid, amidino, (C.sub.1 -C.sub.6) acyl, acylimidoyl, diphosphonomethine or dicarboxymethine group), and R.sup.6 is a hydrogen atom, or a nonsubstituted or substituted benzyl, trialkylsilyl, tert-butyldiphenylsilyl, tetrahydropyranyl or tert-butyl group) or stereoisomers thereof, and pharmaceutically acceptable salts thereof and solvates thereof, and the process for the preparation thereof, and metalloproteinase inhibitors which comprise one or more compounds selected from those compounds as effective ingredients and inhibit matrix metalloproteinases (MMPs) and/or TNF-.alpha. converting enzyme. Furthermore, the preparation intermediates to obtain the compounds of the formula (I) and the process for the preparation.

    摘要翻译: PCT No.PCT / JP96 / 01135 Sec。 371 1997年10月24日第 102(e)1997年10月24日PCT PCT 1996年4月25日PCT公布。 WO96 / 33968 PCT公开号 日期:1996年10月31日新化合物通式(Ⅰ)(其中R1是氢原子,或羟基,芳基(C1-C6)亚烷基或-A-SOn-B基团(A是(C1-C6) 亚烷基; B是(C1-C6)烷基,(C1-C6)酰基,芳基或杂环基; n是0,1或2),R2是氢原子或(C1-C6)烷基, C1-C6)烷氧基10或(C1-C6)烷硫基,R3和R4相同或不同,代表氢原子或(C1-C6)烷基,芳基或芳基(C1-C6)亚烷基,R5是 -YC或C基(Y是(C1-C6)亚烷基,氧原子,亚氨基或(C1-C6)亚烷基亚氨基),C是磺酸,膦酸,脒基,(C1-C6 )酰基,酰亚氨基,二亚膦酰基或二羧基甲基),R6为氢原子,或未取代或取代的苄基,三烷基甲硅烷基,叔丁基二苯基甲硅烷基,四氢吡喃基或叔丁基)或其立体异构体及其药学上可接受的盐及其溶剂合物 ,以及其准备过程 f和金属蛋白酶抑制剂,其包含一种或多种选自那些化合物的化合物作为有效成分并抑制基质金属蛋白酶(MMP)和/或TNF-α转化酶。 此外,制备中间体以获得式(I)化合物及其制备方法。

    Anticoagulant hirudin variants and methods for their production
    7.
    发明授权
    Anticoagulant hirudin variants and methods for their production 失效
    抗凝血水蛭素变体及其生产方法

    公开(公告)号:US5880258A

    公开(公告)日:1999-03-09

    申请号:US909735

    申请日:1997-08-12

    CPC分类号: C07K14/815 A61K38/00

    摘要: The present invention relates to hirudin variants having high anti-thrombin and anti-platelet activity, methods for producing them, and anti-coagulants having said variants as active ingredients.Hirudin variants shown in formula (I) having tyrosine residues or having their hydroxyl group sulfated.Methods for producing hirudin variants by sulfating hydroxyl group of said tyrosine residues, and anti-coagulants having hirudin variants shown in formula (I) as active ingredients.Phe-Glu-A-Ile-Pro-D-Tyr(R) Tyr(R) (I)�In the formula, A represents Glu or Pro, R represents Glu, Tyr (R), Glu-Asp or Glu-Tyr(R), and (R) represents the hydroxy group or its sulfated ester (--O--SO.sub.3 H) of tyrosine residue.!

    摘要翻译: 本发明涉及具有高抗凝血酶和抗血小板活性的水蛭素变体,其制备方法和具有所述变体作为活性成分的抗凝血剂。 具有酪氨酸残基或其羟基硫酸化的式(I)所示的水蛭素变体。 通过硫酸化所述酪氨酸残基的羟基来生产水蛭变异体的方法和具有式(I)所示的水蛭素变体的抗凝血剂作为活性成分。Phe-Glu-A-Ile-Pro-D-Tyr(R)Tyr )(I)[式中,A表示Glu或Pro,R表示Glu,Tyr(R),Glu-Asp或Glu-Tyr(R),(R)表示羟基或其硫酸酯 -SO3H)酪氨酸残基。

    Process for the preparation of D-pantolactone
    8.
    发明授权
    Process for the preparation of D-pantolactone 失效
    制备D-泛酸内酯的方法

    公开(公告)号:US5275949A

    公开(公告)日:1994-01-04

    申请号:US671799

    申请日:1991-04-01

    CPC分类号: C12P7/42 C12P41/003

    摘要: A process for the preparation of D-pantolactone, comprising employing specific microorganisms to convert D,L-pantolactone as the starting material into D-pantoic acid by selective asymmetric hydrolysis of the D-form only in the D,L-pantolactone, and then separating D-pantoic acid and converting it into D-pantolactone.

    摘要翻译: PCT No.PCT / JP90 / 00960 Sec。 371日期1991年4月1日 102(e)1991年4月1日PCT PCT 1990年7月27日PCT公布。 出版物WO91 / 02081 1991年2月21日。一种制备D-泛酸内酯的方法,包括使用特异性微生物将D,L-泛酸内酯作为原料转化成D-泛酸,通过仅在D中的D型的选择性不对称水解 ,L-泛酸内酯,然后分离D-泛解酸并将其转化为D-泛酸内酯。

    Method for determining the .beta.-subunit of human prolyl hydroxylase by
radioimmunoassay to detect hepatic disease
    9.
    发明授权
    Method for determining the .beta.-subunit of human prolyl hydroxylase by radioimmunoassay to detect hepatic disease 失效
    通过放射免疫测定法检测肝脏疾病的人脯氨酰羟化酶的β亚单位的方法

    公开(公告)号:US5130233A

    公开(公告)日:1992-07-14

    申请号:US458435

    申请日:1989-12-28

    摘要: A method for determining human prolyl hydroxylase by radioimmunoassay according to the sandwich method wherein a monoclonal antibody to human prolyl hydroxylase and polyclonal antibody to human prolyl hydroxylase are used, characterized in that a monoclonal antibody to human prolyl hydroxylase is used as at least one of the antibodies which are to be coated on a solid support and to be labeled with a radioactive element. This method is simple and operable with small amounts of samples and gives exact results. Thus, this method is useful for the diagnosis of hepatic diseases. A monoclonal antibody specific to the .beta.-subunit of human prolyl hydroxylase is used to test for the human prolyl hydroxylase.

    摘要翻译: 一种按照夹心法通过放射免疫测定法测定人脯氨酰羟化酶的方法,其中使用人脯氨酰羟化酶的单克隆抗体和人脯氨酰羟化酶的多克隆抗体,其特征在于使用人脯氨酰羟化酶的单克隆抗体作为至少一种 将要涂覆在固体支持物上并用放射性元素标记的抗体。 该方法简单且可操作,少量样品,并给出精确的结果。 因此,该方法对肝脏疾病的诊断有用。 使用对人脯氨酰羟化酶的β亚基特异性的单克隆抗体来测试人脯氨酰羟化酶。

    Chiral phosphinopyrrolidine compounds and their use for asymmetric
synthesis of optically active compounds
    10.
    发明授权
    Chiral phosphinopyrrolidine compounds and their use for asymmetric synthesis of optically active compounds 失效
    手性膦基吡咯烷化合物及其用于不对称合成光学活性化合物的用途

    公开(公告)号:US4985567A

    公开(公告)日:1991-01-15

    申请号:US319186

    申请日:1989-03-06

    摘要: New chiral phosphinopyrrolidine compounds of the general formula: ##STR1## wherein R.sup.1 is hydrogen or --COA.sup.1, --COOA.sup.2, --CONHA.sup.3, --SO.sub.2 A.sup.4 or --PO(A.sup.5).sub.2, A.sup.1, A.sup.2, A.sup.3, A.sup.4 and A.sup.5 each represents independently alkyl or aryl, R.sup.2 is phenyl, di(lower-alkyl)aminophenyl, lower-alkoxyphenyl or 3,5-dimethyl-4-methoxyphenyl, and R.sup.3 is phenyl, lower-alkylphenyl, di(lower-alkyl)aminophenyl, lower-alkoxyphenyl or 3,5-dimethyl-4-methoxyphenyl, with the proviso that R.sup.2 and R.sup.3 may not simultaneously by phenyl, p-di(lower-alkyl)-aminophenyl or p-lower-alkoxyphenyl, as well as the use of these compounds as ligand for a metal complex catalyst for asymmetric synthesis of optically active compounds. The new chiral phosphinopyrrolidine compounds are useful ligands which attain both of high optical yield and high reaction efficiency in catalytic asymmetric reduction.